 CHARLOTTESVILLE, Va., Feb. 11, 2021 GLOBE NEWSWIRE -- Diffusion Pharmaceuticals Inc. NASDAQ: DFFN Diffusion or the Company, an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that it has entered into an underwriting agreement with H.C. Wainwright Co. under which the underwriter has agreed to purchase on a firm commitment basis 9,756,098 shares of common stock of the Company at a price to the public of 1.025 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 17, 2021, subject to satisfaction of customary closing conditions. 